

1 **Title: Does susceptibility to novel coronavirus (COVID-19) infection**
2 **differ by age?: Insights from mathematical modelling**

3 **Authors:** Ryosuke Omori¹, Ryota Matsuyama², Yukihiro Nakata³

4 **Affiliations:**

5 ¹ Research Center for Zoonosis Control, Hokkaido University, Kita-ku, Sapporo-shi,
6 Hokkaido 001-0020, Japan

7 ² Graduate School of Biomedical and Health Sciences, Hiroshima University

8 ³ Department of Physics and Mathematics, Aoyama Gakuin University

9 (Correspondence to Ryosuke Omori at: Address: Kita-20 Nishi-10, Kita-Ku, Sapporo,
10 001-0020, Japan; Tel: +81-11-706-9488, Fax: +81-11-706-9491; Email:
11 omori@czc.hokudai.ac.jp)

12

13

14

15 **Abstract**

16 Among Italy, Spain, and Japan, the age distributions of novel coronavirus (COVID-19)
17 mortality show only small variation even though the number of deaths per country
18 shows large variation. To understand the determinant for this situation, we constructed a
19 mathematical model describing the transmission dynamics and natural history of
20 COVID-19 and analyzed the dataset of fatal cases of COVID-19 in Italy, Spain, and
21 Japan. We estimated the parameter which describes the age-dependency of
22 susceptibility by fitting the model to reported data, taking into account the effect of
23 change in contact patterns during the outbreak of COVID-19, and the fraction of
24 symptomatic COVID-19 infections. Our modelling study revealed that if the mortality
25 rate or the fraction of symptomatic infections among all COVID-19 cases does not
26 depend on age, then unrealistically different age-dependencies of susceptibilities against
27 COVID-19 infections between Italy, Japan, and Spain are required to explain the similar
28 age distribution of mortality but different basic reproduction numbers (R_0). Variation of
29 susceptibility by age itself cannot explain the robust age distribution in mortality by
30 COVID-19 in those three countries, however it does suggest that the age-dependencies
31 of i) the mortality rate and ii) the fraction of symptomatic infections among all COVID-
32 19 cases determine the age distribution of mortality by COVID-19.

33 **Introduction**

34 Since its emergence, coronavirus disease 2019 (COVID-19) has resulted in a
35 pandemic and has produced a huge number of cases worldwide (World Health
36 Organization, 2020). As of May 29, 2020, the number of confirmed cases in Italy was
37 231,139, with 237,141 in Spain, and 16,683 in Japan (World Health Organization,
38 2020). Of those infected, it has been reported that elderly individuals account for a large
39 portion of fatal cases inducing a large heterogeneity in the age distribution of mortality
40 (Dowd et al., 2020; Onder et al., 2020; Wu et al., 2020).

41 The expected value of mortality (the number of deaths, hereafter referred to as
42 mortality) is calculated as the product of the number of cases and the mortality rate
43 among cases (hereafter referred to as mortality rate). As the background mechanism of
44 the heterogeneity of mortality by age, the association of two epidemiological factors
45 with mortality can be considered: i) the age-dependency of susceptibility to infection,
46 which is related to the heterogeneity in the number of cases, and ii) the age-dependency
47 of severity, which is related to the heterogeneity in the mortality rate, e.g. the rate of
48 becoming symptomatic, severe, or fatal case among infected individuals. For the first
49 factor, a high susceptibility for infection will generate a larger number of infections and
50 result in an increase in fatal cases. The possibility of heterogeneity in susceptibility by

51 age was pointed out by the analysis of epidemiological data reported from Wuhan,
52 China (Lee et al., 2020; Wu et al., 2020; Zhang et al., 2020) and from Iceland
53 (Gudbjartsson, 2020). For the second factor, an increase in severity will result in a
54 higher mortality rate and subsequently a rise in the number of fatal cases. This
55 assumption is also reasonable because elder age as well as the existence of
56 comorbidities, which are likely with aging, have been reported as risk factors for severe
57 COVID-19 infections (Bonanad et al., 2020; Guan et al., 2020; Liu et al., 2020; Shi et
58 al., 2020; Verity et al., 2020; Zhou et al., 2020). Although not yet shown in relation to
59 severe acute respiratory syndrome corona virus 2 (SARS Cov-2), which is the causal
60 agent of COVID-19, the presence of age-dependent enhancement of severity has been
61 suggested in SARS coronavirus by the analysis of the innate immune responses in the
62 BALB/c mouse model (Baas et al., 2008; Chen et al., 2010; Roberts et al., 2005).
63 Additionally, it has been suggested that antibody-dependent enhancement (ADE) can
64 contribute to the formation of the observed age-dependency of severity, as suggested in
65 SARS and Middle East respiratory syndrome (MERS) cases (Arabi et al., 2016; Drosten
66 et al., 2014; Tay et al., 2020; Tetro, 2020; Wan et al., 2018; Yang et al., 2005).

67 Interestingly, the age distribution of mortality by COVID-19 (the distribution of
68 the proportion of deaths per age group among all deaths), is similar between Italy,

69 Japan, and Spain, even though the number of deaths are quite different among them
70 (Ministry of Health, Labor and Welfare, 2020; Epicentro, Istituto Superiore di Sanità,
71 2020; Centro de Coordinación de Alertas y Emergencias Sanitarias, 2020). The large
72 difference in the number of deaths between the countries suggests a large difference in
73 their basic reproduction numbers, R_0 s. An independency between age distribution of
74 mortality by COVID-19 and R_0 is suggested. From this independency of age
75 distributions of mortality from R_0 , it can be expected that the contribution of
76 heterogeneity in susceptibility by age to forming the age distribution of mortality is
77 small. That is because, as we will show in this paper, though the age-dependency of
78 severity will naturally produce a proportional effect on the distribution of mortality and
79 result in the formation of robust distributions, when the age-dependency of
80 susceptibility forms the age distribution of mortality, the age distribution of mortality
81 highly depends on R_0 and shows variability.

82 To understand the background of robust age distribution of mortality with varied
83 R_0 , we constructed a mathematical model describing the transmission dynamics of
84 COVID-19 and analyzed the impact of age-dependent susceptibility on the age
85 distribution of mortality. The heterogeneity in social contacts by age may also
86 contribute to the age distribution of mortality. Our model took into account the

87 heterogeneity in social contacts by age and country, and the effect of behavioral change
88 outside of the household during the outbreak. We also estimated and compared the age-
89 dependent susceptibility in Japan, Italy, and Spain to argue the existence of
90 heterogeneity in susceptibility among age groups.

91

92 **Results**

93 Our result shows variation of susceptibility among age groups measured by the
94 exponent parameter φ can explain the age distribution of mortality by COVID-19
95 (figure 2(a)). However, the age distribution of mortality formed by the age-dependency
96 of susceptibility is influenced by the value of R_0 (figure 2(b)), which cannot explain the
97 similarity in age distributions of mortality among Italy, Japan, and Spain. On the other
98 hand, if susceptibility is constant among age groups, the impact of R_0 is quite small on
99 the age distribution of mortality (figure 3).

100 Assuming that the age-dependency of mortality by COVID-19 is determined by
101 only age-dependent susceptibility, i.e., the mortality rate does not depend on age, the
102 exponent parameter, φ , describing the variation of susceptibility among age groups for
103 each country, Italy, Japan, and Spain, was estimated as shown in figure 4. From the
104 difference of the R_0 value and country, the estimated value of φ is largely varied. The

105 impact of reductions in contacts outside of the household on the estimated value of φ
106 was small. The estimate of φ in Italy, assuming a range of $R_0 = 2.4-3.3$ (Zhuang et al.,
107 2020; D'Arienzo and Coniglio, 2020) was 15.0 (95% CI = 14.0-16.0), 16.3 (95% CI =
108 14.9-17.7), and 16.9 (95% CI = 15.4-18.4) for 80%, 40%, and no reduction in contacts
109 outside of the household. For Japan, the estimate of φ assuming $R_0 = 1.7$ (Expert
110 Meeting on the Novel Coronavirus Disease Control, 2020) was 4.2 (95%CI = 3.7-4.9),
111 5.5 (95%CI = 4.9-6.3), and 6.1 (95%CI = 5.4-6.9) for 80%, 40%, and no reduction in
112 contacts outside of the household. When it comes to Spain, the estimate of φ assuming
113 an $R_0 = 2.9$ (Caicedo-Ochoa et al., 2020) was 10.5 (95%CI = 10.4-10.6), 11.7 (95%CI =
114 11.6-11.9), and 12.3 (95%CI = 12.2-12.5) for 80%, 40%, and no reduction in contacts
115 outside of the household.

116 The estimates of φ , assuming that the fraction of infections becoming
117 symptomatic does not depend on age, were also varied by the value of R_0 and by
118 country (figure 5, 6 and 7). Employing the same assumptions of R_0 value, the estimate
119 of φ in Italy was 4.8 (95% CI = 4.2-5.3), 5.4 (95% CI = 4.9-5.9), and 5.7 (95% CI = 5.1-
120 6.2) for 80%, 40%, and no reduction in contacts outside of the household. For Japan, the
121 estimate of φ was 0.0 (95%CI = 0.0-0.9), 0.0 (95%CI = 0.0-1.1), and 0.0 (95%CI = 0.0-
122 1.2) for 80%, 40%, and no reduction in contacts outside of the household. For Spain, the

123 estimate of φ was 1.7 (95%CI = 1.4-1.9), 2.2 (95%CI = 1.9-2.5), and 2.5 (95%CI = 2.1-
124 2.8) for 80%, 40%, and no reduction in contacts outside of the household.

125

126 **Discussion**

127 In the present study, we explored the role of susceptibility to COVID-19 in
128 explaining the age distribution of mortality by COVID-19. Interestingly, the age
129 distributions of mortality from COVID-19 are quite similar between Italy, Japan, and
130 Spain (figure 1). When comparing the age distributions of mortality, only the
131 comparison between Italy and Spain is significant ($p < 0.05$ in Wilcoxon rank sum test
132 with Bonferroni correction). On the other hand, the numbers of deaths are quite
133 different (29,525 for Italy, 400 for Japan, 18,818 for Spain). Indeed, R_0 values are
134 largely different: 2.4-3.3 for Italy (Zhuang et al., 2020; D'Arienzo and Coniglio, 2020),
135 1.7 for Japan (Expert Meeting on the Novel Coronavirus Disease Control, 2020), and
136 2.9 for Spain (Caicedo-Ochoa et al., 2020). If the variation of mortality by age is
137 determined by only the age-dependency of susceptibility, the age distribution of
138 mortality is affected by R_0 as shown in figure 2(b). However, we observed a similarity
139 in age distributions of mortalities between Italy, Japan, and Spain where their R_0 s are
140 quite different. Indeed, unrealistically different φ s among these three countries are

141 required to explain their age distribution of mortality for both settings, i) age-
142 independent mortality, and, ii) the fraction of infections that becomes symptomatic
143 among all COVID-19 cases, f_s , does not depend on age. Although we cannot fully reject
144 the existence of age-dependency in susceptibility, our results suggest that it does not
145 largely depend on age, but rather that age-dependency in severity highly contributes to
146 the formation of the observed age distribution in mortality.

147 The estimates of φ s assuming age independency in symptomatic infections were
148 smaller than those that assumed age independency in mortality. This suggests that the
149 age-dependency of the confirmed case fatality rate (cCFR), which can be biased by the
150 age-dependent difference of the fraction of symptomatic infections among all cases,
151 partially explains the age distribution in mortality. Indeed, when we assumed that the
152 fraction of symptomatic infections was not dependent on age, the estimate of φ in Japan
153 was close to zero in all scenarios regarding the fraction of symptomatic infections,
154 meaning that susceptibility is constant among age groups (figure 5). Although we
155 observed φ s around 5 in Italy and 2 in Spain, this does not mean straightforwardly that
156 susceptibility is age dependent because there is room for an alternative explanation: not
157 susceptibility, but an age-dependent fraction of symptomatic infections can explain this
158 age-dependency. Unfortunately, as we do not yet have detailed data regarding the age-

159 dependent fraction of symptomatic infections and the rate of diagnosis in COVID-19,
160 we cannot conclude which factors (i.e., susceptibility or the fraction of symptomatic
161 infection among all cases) contributed to the observed age-dependency.

162 Wu et al. (2020) showed variation of susceptibility to symptomatic infection by
163 age. This susceptibility can be expressed as the product of the susceptibility and the
164 fraction of symptomatic infection among all cases. To accurately understand
165 susceptibility (i.e., without the constraint of the symptom onset), estimates of the age-
166 dependent fraction of symptomatic infections is required.

167 To understand the mechanism of age-dependency of mortality by COVID-19, an
168 accurate age-dependent mortality rate is required. To estimate the age-dependent
169 mortality rate, an accurate estimate of the case fatality rate is required. However, the
170 number of cases, which is the denominator of the case fatality rate, is difficult to
171 estimate for COVID-19 due to changes in the testing rate (Gostic et al., 2020a; Gostic et
172 al., 2020b; Omori et al. 2020), the change of case definition (Tsang et al. 2020),
173 selection biases (Bar-on et al., 2020), and the delay between the onset of symptoms and
174 death (Linton et al., 2020; Shim et al., 2020; Sun et al., 2020; Verity et al., 2020) as
175 were the cases we experienced in the surveillance of other emerging diseases (Ghani et
176 al., 2005; Garske et al., 2008). To address this problem, implementation of active

177 epidemiological surveillances, such as a large-scale cohort study including real-time

178 detection of infections, should be considered.

179 From the modelling perspective on mortality by Covid-19, age-dependency of
180 severity should be carefully taken into consideration. In particular, in the mathematical
181 models of ADE, the previous models employed three types of assumptions (Woodall
182 and Adams, 2014), the assumption of: increasing susceptibility to infection (Recker et
183 al., 2009; Tang et al., 2018), increasing transmissibility once infection occurred
184 (Ferguson et al., 1999; Ferguson and Andreasen, 2002; Recker et al., 2009), and
185 increasing severity and/or mortality associated with infection (Kawaguchi et al., 2003).

186 Based on our results and from the biological/epidemiological observations of past
187 SARS and MERS cases, the “increasing severity” assumption should be taken into
188 account when analyzing SARS Cov-2 epidemics.

189 In conclusion, the contribution of age-dependency to susceptibility is difficult to
190 use to explain the robust age distribution in mortalities by COVID-19, and it suggests
191 that the age-dependencies of the mortality rate and the fraction of symptomatic
192 infections among all COVID-19 cases determine the age distribution in mortality from
193 COVID-19. Further investigations regarding age-dependency on the fraction of

194 infections becoming symptomatic is required to understand the mechanism behind the
195 mortality by COVID-19 infections.

196

197 **Methods**

198 **1. Data**

199 We analyzed the number of mortalities caused by COVID-19 in Italy reported
200 on 13th May 2020, Japan reported on 7th May 2020, and Spain reported on 12th May
201 2020. The data were collected from public data sources in each country (Ministry of
202 Health, Labor and Welfare, 2020; Epicentro, Istituto Superiore di Sanità, 2020; Centro
203 de Coordinación de Alertas y Emergencias Sanitarias, 2020).

204

205 **2. Model**

206 To understand the background of robust age distribution of mortality with varied
207 R_0 , we employed a mathematical model describing transmissions of COVID-19, an age-
208 structured SEIR model, which can be written as;

$$209 \quad S'_n = -\beta\sigma_n S_n (\sum_m k_{n,m} I_m), \quad (1)$$

$$210 \quad E'_n = \beta\sigma_n S_n (\sum_m k_{n,m} I_m) - \varepsilon E_n, \quad (2)$$

211
$$I'_n = \varepsilon E_n - (\gamma + \delta_n)I_n, \quad (3)$$

212
$$R'_n = \gamma I_n, \quad (4)$$

213
$$D'_n = \delta_n I_n, \quad (5)$$

214 where S_n , E_n , I_n , R_n and D_n represent the proportion of susceptible, latent, infectious,
215 recovered and dead among the entire population, and the subscript index n denotes age
216 group. We stratified the entire population by into eight groups, $n = 1, 2, 3, 4, 5, 6, 7$, and
217 8 for < 10 years old (yo), 10-19 yo, 20-29 yo, 30-39 yo, 40-49 yo, 50-59 yo, 60-69 yo,
218 and 70+ yo. β , $k_{n,m}$, ε , γ and δ_n represent a transmission coefficient, an element of the
219 contact matrix between age group n and m , the progression rate from latent to
220 infectious, recovery rate and mortality rate among age group n , respectively. σ_n denotes
221 the susceptibility of age group n . For the sake of simplicity, births and deaths by other
222 than COVID-19 were ignored. To take into account the effect of behavioral changes
223 outside of the household during the outbreak, $k_{n,m}$ is decomposed by a matrix for
224 contacts within household $k_{in,n,m}$ and that for contacts outside the household $k_{out,n,m}$;

225
$$k_{n,m} = k_{in,n,m} + \alpha k_{out,n,m}, \quad (6)$$

226 where α denotes the reduced fraction of contacts outside of the household. We modelled
227 age specific susceptibility as

228
$$\sigma_n = cn^\varphi. \quad (7)$$

229 Where c is a constant among all age groups, φ denotes the exponent parameter
230 describing the variation of susceptibility among age groups. An increase in φ means an
231 increase in the variation of susceptibility among age groups, and $\varphi=0$ means that
232 susceptibility is equal among all age groups

233

234 **3. Parameterizations**

235 We parameterized ε and γ using the values from a previous modelling study of COVID-
236 19 (Prem et al., 2020). We referred to the contact matrices for Italy, Japan, and Spain
237 from Prem et al. (Prem et al., 2017). β and c were controlled such that the basic
238 reproduction number, R_0 , becomes arbitral values. R_0 was calculated by constructing a
239 next generation matrix (Diekman and Heesterbeek, 2000; Mossong et al., 2008) using
240 each country's demographic data obtained from a public data source (United Nations,
241 2020).

242

243 **4. Fitting**

244 We calculated the proportions of deaths in the age group n among all deaths, d_n
245 ($= D_n(\infty) / \sum_n D_n(\infty)$), and fitted them to the observed data in each country. The
246 mortality rate among age group n , δ_n , is required to calculate d_n , however, a reliable
247 estimate of δ_n for COVID-19 is difficult to obtain. Due to the uncertainty of the fraction
248 of symptomatic infections per age group, δ_n is difficult to estimate from observed data,
249 i.e., the confirmed case fatality rate among age group n ($cCFR_n$). Since an estimate of δ_n
250 is difficult to obtain, we employed two different settings to calculate d_n , i) δ_n is assumed
251 to be a constant among all age groups, or, ii) δ_n is calculated from $cCFR_n$ assuming that
252 the fraction of symptomatic infections among all COVID-19 cases (f_s) is not dependent
253 with age.

254 In setting i), the value of δ_n is not required to estimate d_n once the value of R_0 is
255 given. We calculated d_n by calculating the proportions of recovered persons per age
256 group among all recovered persons $R_n(\infty) / \sum_n R_n(\infty)$ instead of $D_n(\infty) / \sum_n D_n(\infty)$.
257 In our model, shown in equation (1)-(4), $R_n(\infty) / \sum_n R_n(\infty)$ is determined by the value
258 of R_0 completely when all parameter values other than β and δ_n are fixed, and

259 $D_n(\infty)/\sum_n D_n(\infty) = R_n(\infty)/\sum_n R_n(\infty)$ if $\delta_n \neq 0$. The proof can be found in
260 supplementary file 1.

261 The assumption in setting i), δ_n is constant among all age groups, may be too
262 strong for the COVID-19 epidemic. To take into account the age-dependency of
263 mortality by COVID-19, δ_n was calculated from the $cCFR_n$ assuming that f_s is not
264 dependent with age. As for the setting ii), assuming three scenarios; $f_s = 0.05, 0.25,$ and
265 $0.5,$ δ_n for each country were calculated using $cCFR_n$ in each country. We obtained δ_n
266 by solving $cCFR_n = \delta_n/[f_s(\delta_n + \gamma)]$.

267 We solved the model shown in equations (1)-(5) numerically, and d_n was
268 calculated after sufficient time was given to finish the epidemics. We estimated φ using
269 a log likelihood function describing the multinomial sampling process of deaths per age
270 group;

$$271 \quad \sum_n D_n \log[d_n(\varphi)]. \quad (8)$$

272 Maximum likelihood estimates of φ with given R_0 were obtained by maximizing
273 equation (8) and the profile likelihood-based confidence intervals were computed.

274

275 **Acknowledgement**

276 The authors gratefully acknowledge the manuscript language review of Dr Heidi L.

277 Gurung.

278 **Competing interests**

279 The authors declare no conflicts of interest.

280 **Funding source**

281 R.O. acknowledges support from the Japan Society for the Promotion of Science (JSPS)
282 Grant-in-Aid for Young Scientists 19K20393. Y.N. was supported by JSPS Grant-in-
283 Aid for Young Scientists (B) 16K20976. The funders had no role in study design, data
284 collection and analysis, decision to publish, or preparation of the manuscript.

285 **Ethical approval**

286 This study was based on publicly available data and did not require ethical approval.

287

288 **References**

- 289 1. World Health Organization. Coronavirus disease (COVID-2019) situation reports -
290 130. Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
291 2019/situation-reports. (Accessed 29th May 2020)
- 292 2. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, Liu Y, Mills MC.
293 Demographic science aids in understanding the spread and fatality rates of COVID-
294 19. *Proc Natl Acad Sci.* 2020; 117(18):9696-9698. doi:10.1073/pnas.2004911117.
- 295 3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients
296 Dying in Relation to COVID-19 in Italy. *JAMA.* 2020;323:1775-1776.
297 doi:10.1001/jama.2020.4683
- 298 4. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ,
299 Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the

- 300 transmission dynamics in Wuhan, China. *Nat Med.* 2020;26:506-510.
301 doi:10.1038/s41591-020-0822-7
- 302 5. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to
303 COVID-19?. *J Microbiol Immunol Infect.* 2020;S1684-1182(20)30039-6.
304 doi:10.1016/j.jmii.2020.02.011
- 305 6. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y. Clinical
306 characteristics of 140 patients infected with SARS - CoV - 2 in Wuhan, China.
307 *Allergy.* 2020;0:1-12. doi:10.1111/all.14238
- 308 7. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl
309 GL, Saemundsdottir J, Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B,
310 Fridriksdottir R, Gardarsdottir EE, Georgsson G, Gretarsdottir OS, Gudmundsson
311 KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO, Jonasdottir A, Jonsson
312 F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L, Sigmundsdottir G,
313 Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA,
314 Thorbjornsson B, Löve A, Masson G, Jonsdottir I, Möller AD, Gudnason T,
315 Kristinsson KG, Thorsteinsdottir U, Stefansson K. Spread of SARS-CoV-2 in the
316 Icelandic Population. *N Engl J Med.* 2020;NEJMoa2006100.
317 doi:10.1056/NEJMoa2006100.
- 318 8. Bonanad C, García-Blasabe S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-
319 González V, Fácila L, Ariza A, Núñez J, Cordero A. The effect of age on mortality
320 in patients with Covid-19: a metanalysis with 611,583 subjects. *J Am Med Dir*
321 *Assoc.* 2020;In Press. doi:10.1016/j.jamda.2020.05.045
- 322 9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui
323 DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,
324 Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P,
325 Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong

- 326 NS. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics
327 of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.
328 doi: 10.1056/NEJMoa2002032.
- 329 10. Liu k, Chen Y, Lin R, Han K., Clinical features of COVID-19 in elderly patients: A
330 comparison with young and middle-aged patients. *J Infect*. 2020;80(6): e14-e18.
331 doi:10.1016/j.jinf.2020.03.005
- 332 11. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe
333 COVID-19 and establishment of a host risk score: findings of 487 cases outside
334 Wuhan. *Crit Care*. 2020;24(1):108. doi:10.1186/s13054-020-2833-7.
- 335 12. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-
336 Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin
337 M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green
338 W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S,
339 Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM.
340 Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The*
341 *Lancet Infectious Diseases*. 2020;30:S1473-3099(20)30243-7. doi:10.1016/S1473-
342 3099(20)30243-7
- 343 13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan
344 L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
345 risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
346 retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.
347 doi:10.1016/S0140-6736(20)30566-3.
- 348 14. Baas T, Roberts A, Teal TH, Vogel L, Chen J, Tumpey TM, Katze MG, Subbarao
349 K. Genomic analysis reveals age-dependent innate immune responses to severe
350 acute respiratory syndrome coronavirus. *J Virol*. 2008;82(19):9465-76. doi:
351 10.1128/JVI.00489-08
- 352 15. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K.
353 Cellular immune responses to severe acute respiratory syndrome coronavirus

- 354 (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in
355 control of SARS-CoV infection. *J Virol.* 2010;84(3):1289-301.
356 doi:10.1128/JVI.01281-09
- 357 16. Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. Aged BALB/c mice
358 as a model for increased severity of severe acute respiratory syndrome in elderly
359 humans. *J Virol.* 2005;79(9):5833-8. doi:10.1128/JVI.79.9.5833-5838.2005
- 360 17. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A,
361 Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A,
362 Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of
363 Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi
364 Arabia. *Emerg Infect Dis.* 2016;22(9):1554-61. doi:10.3201/eid2209
- 365 18. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, Madani H,
366 Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak
367 AM, Al-Tawfiq JA, Zumla AI, Memish ZA. Transmission of MERS-coronavirus in
368 household contacts. *N Engl J Med.* 2014;371(9):828-35.
369 doi:10.1056/NEJMoa1405858
- 370 19. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
371 immunity, inflammation and intervention. *Nat Rev Immunol.* 2020;20(6):363-374.
372 doi:10.1038/s41577-020-0311-8
- 373 20. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect.*
374 2020;22(2):72-73. doi:10.1016/j.micinf.2020.02.006
- 375 21. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou
376 Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of
377 Coronavirus Entry. *J Virol.* 2020;94(5):e02015-19. doi:10.1128/JVI.02015-19.
- 378 22. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ.
379 Evasion of antibody neutralization in emerging severe acute respiratory syndrome

- 380 coronaviruses. Proc Natl Acad Sci. 2005;102(3):797-801.
381 doi:10.1073/pnas.0409065102
- 382 23. Ministry of Health, Labour and Welfare, Japan. Documents for press release. –
383 Available at <https://www.mhlw.go.jp/content/10906000/000628510.pdf>. (In
384 Japanese, accessed on 13th May 2020)
- 385 24. EpiCentro, Istituto Superiore di Sanità. Infographic available in English - 13 may
386 2020 update in COVID-19 integrated surveillance: key national data. Available at
387 <https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data>.
388 (Accessed on 13th May 2020)
- 389 25. Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 103.
390 Enfermedad por el coronavirus (COVID-19). 12.05.2020. Available at
391 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_103_COVID-19.pdf)
392 [China/documentos/Actualizacion_103_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_103_COVID-19.pdf). (In Spanish, accessed 13th
393 May 2020)
- 394 26. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, Yang S, He D, Xiao L.
395 Preliminary estimates of the reproduction number of the coronavirus disease
396 (COVID-19) outbreak in Republic of Korea and Italy by 5 March 2020. Int J Infect
397 Dis. 2020;95:308-310. doi:10.1016/j.ijid.2020.04.044
- 398 27. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction
399 number, R₀, based on the early phase of COVID-19 outbreak in Italy. Biosafety
400 and Health. 2020;In Press. doi:10.1016/j.bsheal.2020.03.004
- 401 28. Expert Meeting on the Novel Coronavirus Disease Control. The minutes of the fifth
402 meeting. 2020 March 2. Available at:
403 [https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.](https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.pdf)
404 [pdf](https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.pdf). (In Japanese, accessed 13th May 2020)
- 405 29. Caicedo-Ochoa Y, Rebellón-Sánchez DE, Peñaloza-Rallón M, Cortés-Motta HF,
406 Méndez-Fandiño YR. Effective Reproductive Number Estimation for Initial Stage
407 of COVID-19 Pandemic in Latin American Countries. Int J infect Dis.
408 2020;95:316-318. doi:10.1016/j.ijid.2020.04.069
- 409 30. Gostic K, Gomez ACR, Kucharski AJ, Lloyd-Smith JO. Effectiveness of traveller
410 screening for emerging pathogens is shaped by epidemiology and natural history of
411 infection. Elife. 2020; 2015;4: e05564. doi: 10.7554/eLife.05564
- 412 31. Gostic K, Gomez ACR, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated
413 effectiveness of symptom and risk screening to prevent the spread of COVID-19.
414 Elife. 2020; 9. doi: 10.7554/eLife.55570

- 415 32. Omori R, Mizumoto K, Chowell G. Changes in testing rates could mask the novel
416 coronavirus disease (COVID-19) growth rate. *Int J Infect Dis.* 2020;94:116-118.
417 doi:10.1016/j.ijid.2020.04.021
- 418 33. Tsang TK, Wu P, Lin Y, Lau EH, Leung GM, Cowling BJ. Effect of changing case
419 definitions for COVID-19 on the epidemic curve and transmission parameters in
420 mainland China: a modelling study. *Lancet Public Health.* 2020; 5; 5; e289-e296.
421 doi:10.1016/S2468-2667(20)30089-X.
- 422 34. Bar-on YM, Flamholz A, Phillips R, and Milo R. SARSCoV-2 (COVID-19) by the
423 numbers. *Elife.* 2020;9:e57309. doi: 10.7554/eLife.57309
- 424 35. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan
425 B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological
426 Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A
427 Statistical Analysis of Publicly Available Case Data. *J Clin Med.* 2020;9(2):538.
428 doi:10.3390/jcm9020538
- 429 36. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity
430 of COVID-19 in South Korea. *Int J Infect Dis.* 2020;93:339-344. doi:
431 10.1016/j.ijid.2020.03.031
- 432 37. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus
433 disease 2019 outbreak based on crowdsourced data: a population-level
434 observational study. *Lancet Digital Health.* 2020;2:e201–e208. doi:10.1016/S2589-
435 7500(20)30026-1
- 436 38. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, Ho LM, Chan
437 WS, Anderson RM, Hedley AJ, Leung GM. Methods for estimating the case
438 fatality ratio for a novel, emerging infectious disease. *Am J Epidemiol.*
439 2005;162:479-486. doi:10.1093/aje/kwi230
- 440 39. Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Ferguson
441 NM, Ghani AC. Assessing the severity of the novel influenza A/H1N1 pandemic.
442 *BMJ.* 2008;339;b2840. doi: 10.1136/bmj.b2840
- 443 40. Woodall H, Adams B. Partial cross-enhancement in models for dengue
444 epidemiology. *J Theor Biol.* 2014;351:67-73. doi: 10.1016/j.jtbi.2014.02.016
- 445 41. Recker M, Blyuss KB, Simmons CP, Hien TT, Wills B, Farrar J, Gupta S.
446 Immunological serotype interactions and their effect on the epidemiological pattern
447 of dengue. *Proc Biol Sci.* 2009 Jul 22;276(1667):2541-8. doi:

- 448 10.1098/rspb.2009.0331. Epub 2009 Apr 15. PMID: 19369266; PMCID:
449 PMC2684681.
- 450 42. Tang B, Huo X, Xiao Y, Ruan S, Wu J. A conceptual model for optimizing vaccine
451 coverage to reduce vector-borne infections in the presence of antibody-dependent
452 enhancement. *Theor Biol Med Model*. 2018;15(1):13. doi:10.1186/s12976-018-
453 0085-x
- 454 43. Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent enhancement
455 on the transmission dynamics and persistence of multiple-strain pathogens. *Proc*
456 *Natl Acad Sci*. 1999;96(2):790-4. doi:10.1073/pnas.96.2.790.
- 457 44. Ferguson N, Andreasen V. The influence of different forms of cross-protective
458 immunity on the population dynamics of antigenetically diverse populations.
459 Castillo-Chavez C, Blower S, Kirschner D, van den Driessche P, Yakubu A (Eds.),
460 *Mathematical Approaches for Emerging and Reemerging Infectious Diseases:*
461 *Models, Methods and Theory*. IMA Volumes Mathematics and its Applications,
462 vol. 126, Kluwer Academic Publishers, New York. 2002;157-169.
- 463 45. Kawaguchi I, Sasaki A, Boots M. Why are dengue virus serotypes so distantly
464 related? Enhancement and limiting serotype similarity between dengue virus
465 strains. *Proc Biol Sci*. 2003;270(1530):2241-7. doi:10.1098/rspb.2003.2440
- 466 46. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N. The effect of
467 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic
468 in Wuhan, China: a modelling study. *Lancet Public Health*. 2020;e261-e270.
469 doi:10.1016/S2468-2667(20)30073-6
- 470 47. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using
471 contact surveys and demographic data. *PLoS Comput Biol*. 2017;13(9):e1005697.
472 doi:10.1371/journal.pcbi.1005697
- 473 48. Diekmann O, Heesterbeek JAP. *Mathematical epidemiology of infectious diseases.*
474 *Model building, analysis and interpretation*. 2000;Chichester (UK):Wiley.
- 475 49. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social
476 Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. *PLoS*
477 *Med*. 2008;5(3):e74. doi:10.1371/journal.pmed.0050074
- 478 50. United Nations, 2020. Annual Population Indicators in Standard Projections.
479 Available at <https://population.un.org/wpp/Download/Standard/Interpolated/>.
480 (Accessed 13th May 2020)


481

482

483 **Figures**

484

485 Figure 1: The age distribution of mortality by COVID-19 in Italy reported on 13th May
486 2020, Japan reported on 7th May 2020, and Spain reported on 12th May 2020. Circle,
487 square, and “+” denote Italy, Japan, and Spain.




488

489


490

491 Figure 2: The sensitivity of (a) age-dependency of susceptibility and (b) transmission
492 coefficient β against age distribution of mortality when age-independent mortality was
493 assumed. In panel (a), all parameters except the exponent parameter φ , describing the
494 variation of susceptibility among age groups, were fixed and parameterized as $R_0 = 2.9$
495 in the setting for Spain. In panel (b), all parameters parameterized as the setting for
496 Spain ($\varphi=12.3$) except were fixed except transmission coefficient β .




497
498

499 Figure 3: The sensitivity of transmission coefficient β against age distribution of
500 mortality when it was assumed that age-dependent mortality was proportional to cCFR
501 per age group. All parameters were fixed and parameterized as the setting for Spain
502 except the transmission coefficient β .




503
504

505 Figure 4: The estimate of exponent parameter ρ describing the variation of
506 susceptibility among age groups assuming that mortality rate does not depend on age.
507 True and broken lines represent the maximum likelihood estimates and 95% confidence
508 intervals, respectively.



509
510
511

512 Figure 5: The estimate of exponent parameter φ describing the variation of
513 susceptibility among age groups assuming that mortality rate does not depend on age
514 and the fraction of infections that becomes symptomatic among all COVID-19 cases is
515 0.25. True and broken lines represent the maximum likelihood estimates and 95%
516 confidence intervals, respectively.




517

518

519

520 Figure 6: The estimate of exponent parameter φ describing the variation of
521 susceptibility among age groups assuming that mortality rate does not depend on age
522 and the fraction of infections that becomes symptomatic among all COVID-19 cases is
523 0.5. True and broken lines represent the maximum likelihood estimates and 95%
524 confidence intervals, respectively.




525

526

527

528 Figure 7: The estimate of exponent parameter φ describing the variation of
529 susceptibility among age groups assuming that mortality rate does not depend on age
530 and the fraction of infections that becomes symptomatic among all COVID-19 cases is
531 0.05. True and broken lines represent the maximum likelihood estimates and 95%
532 confidence intervals, respectively.



533

534